Infectious Diseases
COVID-19 has raised the importance of research into fighting infectious diseases that threaten populations.
Optimising vaccine follow-up through early planning
This whitepaper discusses the role of patient tokenisation in vaccine follow-up and the importance of early planning, considerations for long-term follow-up design, and elements of ensuring secure long-term follow up.
Investing in Anti-HIV
How HIV therapeutic developers can reshape the future of HIV control.
In this whitepaper we explore the persistent challenges in HIV therapeutic development, including biological, behavioral, and sociocultural factors impacting efficacy. Discover recent innovations such as long-acting injectables, vaccines, curative strategies, and best practices for trial design, diagnostics, and community engagement.
COVID-19 vaccines: Post-authorisation safety surveillance
This whitepaper explores the multifaceted challenges of COVID-19 post-authorisation safety surveillance studies and how business intelligence tools can benefit these efforts.
Assessing strategies for mitigating infectious diseases
Public health officials turn to evidence as the basis for their health policies to control the spread of infections. However, many nuanced factors can influence variations in the number of infections caused by a single infected individual.
Watch the webinar: An introduction to infectious disease modelling
In this whitepaper, we explain the basic measures used to quantify infectious disease transmission and introduce the principles of dynamic modelling to inform the selection of the most effective and cost-efficient strategies for mitigating infectious diseases.
Fortifying vaccines: Preparation and prevention against future infectious disease epidemics
This whitepaper presents infrastructural and strategic considerations for strengthening vaccine development so that the medical community will be prepared to respond to future pandemics and novel diseases.
Antimicrobial resistance
The World Health Organization calls antimicrobial resistance, resulting from the overuse of antibiotics or other drugs, one of the top 10 public health threats. In fact, the next global pandemic could be another novel respiratory pathogen of zoonotic origins or a multidrug resistant strain of a previously eradicated pathogen.
In this whitepaper we provide a framework for understanding the antimicrobial crisis and the role healthcare and biopharma industries have to play in mitigating the impact of future pandemics.
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
HIV infographic
HIV treatments: What has been achieved?
Before antiretroviral treatment availability, life expectancy for a person living with HIV was reduced by approximately 12.5 years. Now, this same individual will have near-normal life expectancy.
Infectious diseases and vaccines blogs
Beyond tradition: An analysis of modern vaccine technologies
This blog explores some of the most promising non-viral vaccine development platforms, highlighting their mechanisms, advantages, and limitations.
Why long-term follow-up should start early in vaccine trials
Learn more about why demonstrating long-term safety should start early in vaccine trials. With early planning, vaccine developers can gather real-world data and evidence needed to help individuals make informed decisions about vaccination.
Technology and tokenisation: Reflections from the 2025 World Vaccine Congress
Dive into the main themes, topics and outlooks from the 2025 WVC, held in Washington, D.C., where ICON presented and was recognised at the ViE Awards.
The race to develop combination vaccines – and the importance of indirect effects
A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19.
Disease surveillance in low- and middle-income countries
Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks.
Disease surveillance and innovative vaccines
Learn about current approaches to disease surveillance and why they are important for the advancement of vaccine development in this blog.
Pre-emptive vaccine research to improve EID response
This blog explores strategies for strengthening vaccine development so that the medical community is better prepared to respond to future epidemics.
From clinician visits to data analysis: the challenges and solutions in COVID vaccine pharmacovigilance
Learn more about the challenges and solutions in assessing the long-term effects of Covid and Covid vaccines in this blog.
Infectious diseases and vaccines media contributions
-
Media article: Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
-
Media article: Has the pandemic enabled us to accelerate the pace of drug development?
Nuala Murphy contributes to this Marvellous Medicine BBC4 podcast about accelerating the pace of drug development due to the pandemic.
-
Media article: A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
Media article: Smart people: Dr. Steve Cutler
PharmaTimes talks to Dr Steve Cutler, CEO at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials.
-
Media article: The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
Media article: A challenge of pandemic proportions
ICON CEO Steve Cutler, discusses running the Pfizer / BioNTech vaccine trial, and how it proved the value of partnership, and the key role of technology.
-
Media article: US Regulators question AstraZeneca vaccine trial data
ICON's Dr. Andrew Garrett, Executive Vice President of Scientific Operations, weighs in on potential safety issues with the AstraZeneca COVID-19 vaccine.
-
Media article: What does it really take to conduct a vaccine trial at scale?
Dr Nuala Murphy, President of Clinical Services, talks exclusively to Pharmafield about the Pfizer/BioNTech COVID-19 vaccine trial and the implications this has on the future of drug development.
Receive more insights on infectious diseases and vaccines from ICON
Please visit ICON's Preference Centre and select 'Infectious Diseases and Vaccines' under 'Therapeutic Areas of Interest' to receive new insights on infectious diseases and vaccines.
Infectious diseases and vaccines services
ICON’s extensive Infectious Disease expertise enables us to consistently select the best sites, expedite start-up timelines, and achieve enrolment targets for our clients. We apply proven strategies to clinical trials that minimise risk and generate high-quality, reliable data reducing the time and cost of bringing new therapies to market.